Sutro Biopharma, Inc.
corporate_fare Company Profile
Sutro Biopharma, Inc. (NASDAQ:STRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for STRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for STRO spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- Sutro 10-Q: Q3 Revenue $9.1M Misses, Cash $142.2M Funds Runway Into 1H 2028
- Sutro Q3 Revenue Misses Estimates at $9.1M, Net Loss Widens to $31.5M
- Sutro Biopharma Plunges 24% as STRO-004 Update Disappoints
- Sutro's STRO-004 Shows Early Responses in Phase 1, Cash Runway Extended to Q2 2028
- Q1 Net Loss Halved, Cash Position Boosted by $110M Offering, Extending Runway
Financial Snapshot
Short Interest & Short Volume
6.26 days to coverFINRA reported short interest of 2,257,487 shares in STRO as of the October 30, 2026 settlement, a 15.1% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 74.0% of STRO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.